Physician profile
Mark A Pifer
NPI 1881762011
$641.89
in general payments reported to CMS, 2019-2025
13 companies · $95.86 in 2025
The $95.86 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.73 · 2021: $29.84 · 2022: $85.10 · 2023: $113 · 2024: $250 · 2025: $95.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $170.69 | 2024-2025 | Krystexxa |
| Nevro Corp. | $160.56 | 2023-2024 | Senza |
| Ibsa Pharma INC. | $61.11 | 2021-2023 | Tirosint, Licart |
| Horizon Therapeutics Plc | $55.48 | 2022-2023 | Krystexxa |
| Osiris Therapeutics INC. | $35.16 | 2019 | |
| Medtronic, INC. | $25.66 | 2024 | Intellis Adaptivestim |
| Paratek Pharmaceuticals, INC. | $24.43 | 2024 | Nuzyra |
| Organogenesis INC. | $23.10 | 2022 | |
| Orthofix Medical, INC. | $21.99 | 2019-2021 | |
| Cardiovascular Systems INC. | $19.52 | 2022 | |
| Convatec INC. | $15.78 | 2023 | |
| Sandoz INC. | $15.21 | 2019 | |
| Averitas Pharma INC. | $13.20 | 2023 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pifer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.